Although anti-TNF agents are the primary therapeutic option for patients with IBD with complications, nearly two-thirds of patients experience either a primary nonresponse or a secondary loss of response to anti-TNF agents, and the risks of infection and malignancy of anti-TNF agents should be considered (44). This evidence concerns the gene TNF and infection.